211 related articles for article (PubMed ID: 38186683)
1. Impact of guideline adherence on the prognosis of Barcelona clinic liver cancer stage B hepatocellular carcinoma.
Han JE; Cho HJ; Cheong JY; Lim SG; Yang MJ; Noh CK; Lee GH; Kim SS
World J Gastroenterol; 2023 Dec; 29(47):6122-6137. PubMed ID: 38186683
[TBL] [Abstract][Full Text] [Related]
2. Transarterial Chemoembolization versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma after Resection within Barcelona Clinic Liver Cancer Stage 0/A: A Retrospective Comparative Study.
Chen R; Gan Y; Ge N; Chen Y; Wang Y; Zhang B; Wang Y; Ye S; Ren Z
J Vasc Interv Radiol; 2016 Dec; 27(12):1829-1836. PubMed ID: 27553917
[TBL] [Abstract][Full Text] [Related]
3. BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group.
Farinati F; Vanin V; Giacomin A; Pozzan C; Cillo U; Vitale A; Di Nolfo AM; Del Poggio P; Benvegnu' L; Rapaccini G; Zoli M; Borzio F; Giannini EG; Caturelli E; Trevisani F;
Liver Int; 2015 Jan; 35(1):223-31. PubMed ID: 25074434
[TBL] [Abstract][Full Text] [Related]
4. Comparison of overall survival on surgical resection versus transarterial chemoembolization with or without radiofrequency ablation in intermediate stage hepatocellular carcinoma: a propensity score matching analysis.
Lin CW; Chen YS; Lo GH; Hsu YC; Hsu CC; Wu TC; Yeh JH; Hsiao P; Hsieh PM; Lin HY; Shu CW; Hung CM
BMC Gastroenterol; 2020 Apr; 20(1):99. PubMed ID: 32272898
[TBL] [Abstract][Full Text] [Related]
5. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system.
Han K; Kim JH
World J Gastroenterol; 2015 Sep; 21(36):10327-35. PubMed ID: 26420959
[TBL] [Abstract][Full Text] [Related]
6. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study.
Ren Y; Cao Y; Ma H; Kan X; Zhou C; Liu J; Shi Q; Feng G; Xiong B; Zheng C
BMC Cancer; 2019 Oct; 19(1):983. PubMed ID: 31640620
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Combined Radiofrequency Ablation with Transarterial Chemoembolization in Patients with Barcelona Clinic Liver Cancer Stage A Hepatocellular Carcinoma Ineligible for Curative Treatment.
Kim AR; Park E; Kwon SY; Park SJ; Kim YJ; Yoo BC; Choe WH; Kim JH; Hwang JH; Park SW; Kim YJ; Park HS; Yu MH; Jeon HJ
Korean J Gastroenterol; 2019 Mar; 73(3):167-176. PubMed ID: 31013560
[TBL] [Abstract][Full Text] [Related]
8. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
[TBL] [Abstract][Full Text] [Related]
9. Optimizing the management of patients with BCLC stage-B hepatocellular carcinoma: Modern surgical resection as a feasible alternative to transarterial chemoemolization.
Ciria R; López-Cillero P; Gallardo AB; Cabrera J; Pleguezuelo M; Ayllón MD; Luque A; Zurera L; Espejo JJ; Rodríguez-Perálvarez M; Montero JL; de la Mata M; Briceño J
Eur J Surg Oncol; 2015 Sep; 41(9):1153-61. PubMed ID: 26118317
[TBL] [Abstract][Full Text] [Related]
10. Treatment choice for early-stage hepatocellular carcinoma in real-world practice: impact of treatment stage migration to transarterial chemoembolization and treatment response on survival.
Roberts SK; Gazzola A; Lubel J; Gow P; Bell S; Nicoll A; Dev A; Fink MA; Sood S; Knight V; Hong T; Paul E; Mishra G; Majeed A; Kemp W;
Scand J Gastroenterol; 2018; 53(10-11):1368-1375. PubMed ID: 30394145
[TBL] [Abstract][Full Text] [Related]
11. Transcatheter Arterial Chemoembolization With or Without Radiofrequency Ablation: Outcomes in Patients With Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma.
Hirooka M; Hiraoka A; Ochi H; Kisaka Y; Joko K; Michitaka K; Hiasa Y
AJR Am J Roentgenol; 2018 Apr; 210(4):891-898. PubMed ID: 29412017
[TBL] [Abstract][Full Text] [Related]
12. Liver resection versus transarterial chemoembolization for the initial treatment of Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma.
Yang B; Zheng B; Yang M; Zeng Z; Yang F; Pu J; Li C; Liao Z
Hepatol Int; 2018 Sep; 12(5):417-428. PubMed ID: 30073454
[TBL] [Abstract][Full Text] [Related]
13. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations?: an observational study of the HCC East-West study group.
Torzilli G; Belghiti J; Kokudo N; Takayama T; Capussotti L; Nuzzo G; Vauthey JN; Choti MA; De Santibanes E; Donadon M; Morenghi E; Makuuchi M
Ann Surg; 2013 May; 257(5):929-37. PubMed ID: 23426336
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas.
Ni JY; Kong J; Sun HL; Chen YT; Luo JH; Wang WD; Chen D; Jiang XY; Xu LF
Acad Radiol; 2018 Apr; 25(4):423-429. PubMed ID: 29198946
[TBL] [Abstract][Full Text] [Related]
15. Barcelona clinic liver cancer stage B hepatocellular carcinoma: transarterial chemoembolization or hepatic resection?
Jianyong L; Lunan Y; Wentao W; Yong Z; Bo L; Tianfu W; Minqing X; Jiaying Y
Medicine (Baltimore); 2014 Nov; 93(26):e180. PubMed ID: 25474433
[TBL] [Abstract][Full Text] [Related]
16. Refractoriness to transarterial chemoembolization in patients with recurrent hepatocellular carcinoma after curative resection.
Jeon MY; Kim HS; Lim TS; Han DH; Kim BK; Park JY; Kim DY; Ahn SH; Choi GH; Choi JS; Han KH; Kim SU
PLoS One; 2019; 14(4):e0214613. PubMed ID: 30947275
[TBL] [Abstract][Full Text] [Related]
17. The adherence to the American Association for the Study of Liver Diseases 2018 guidelines in the management of hepatocellular carcinoma and its impact on survival.
Manne A; Mulekar M; Escobar D; Prodduturvar P; Fahmawi Y; Henderson P; Abdul-Rahim O; Hussain Z; Liles S; Fonseca A; Howard JH; Mneimneh W; Gilbert R; Alkharabsheh O; Pai S; White ZB; Nelson C; Khushman M
J Cancer Res Ther; 2023; 19(5):1103-1108. PubMed ID: 37787270
[TBL] [Abstract][Full Text] [Related]
18. HKLC Triages More Hepatocellular Carcinoma Patients to Curative Therapies Compared to BCLC and Is Associated with Better Survival.
Wallace MC; Huang Y; Preen DB; Garas G; Adams LA; MacQuillan G; Tibballs J; Ferguson J; Samuelson S; Jeffrey GP
Dig Dis Sci; 2017 Aug; 62(8):2182-2192. PubMed ID: 28547649
[TBL] [Abstract][Full Text] [Related]
19. Transarterial Chemoembolization in Treatment-Naïve and Recurrent Hepatocellular Carcinoma: A Propensity-Matched Outcome Analysis.
Kim DS; Lim TS; Jeon MY; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Baatarkhuu O; Kim SU
Dig Dis Sci; 2019 Dec; 64(12):3660-3668. PubMed ID: 31187326
[TBL] [Abstract][Full Text] [Related]
20. Factors predicting long-term outcomes of early-stage hepatocellular carcinoma after primary curative treatment: the role of surgical or nonsurgical methods.
Kuo MJ; Mo LR; Chen CL
BMC Cancer; 2021 Mar; 21(1):250. PubMed ID: 33685409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
